Related Experiment Videos

Familial breast-ovarian cancer syndromes: BRCA1 and BRCA2

A Berchuck¹, M Carney, J M Lancaster

¹Department of Obstetrics, Duke University Medical Center, Durham, NC 27710, USA.

Clinical Obstetrics and Gynecology

|March 21, 1998

Abstract

No abstract available in PubMed .

Related Concept Videos

Articles linked to this work by shared authors, journal, and citation graph.

Prognostic gene expression signature for high-grade serous ovarian cancer.

Annals of oncology : official journal of the European Society for Medical Oncology·2020

Intraperitoneal chemotherapy following neoadjuvant chemotherapy and optimal interval tumor reductive surgery for advanced ovarian cancer.

Gynecologic oncology·2020

Modes of delivery of genetic testing services and the uptake of cancer risk management strategies in BRCA1 and BRCA2 carriers.

Clinical genetics·2013

Upregulation of miRNA-155 promotes tumour angiogenesis by targeting VHL and is associated with poor prognosis and triple-negative breast cancer.

Oncogene·2013

In vitro analysis of ovarian cancer response to cisplatin, carboplatin, and paclitaxel identifies common pathways that are also associated with overall patient survival.

British journal of cancer·2012

Role of common genetic variants in ovarian cancer susceptibility and outcome: progress to date from the Ovarian Cancer Association Consortium (OCAC).

Journal of internal medicine·2012

See all related articles